ROR1 and mantle cell lymphoma: This pathway may be blocked by cirmtuzumab, a first-in-class humanized anti-ROR1 mAb, which is being evaluated in patients with CLL or MCL (https://clinicaltrials.gov/ct2/show/NCT02222688) [11, 48].